- Home
- GRFX vs PMN Comparison
GRFX vs PMN Comparison
Compare GRFX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFX
- PMN
- Stock Information
- Founded
- GRFX 1981
- PMN 2004
- Country
- GRFX Hong Kong
- PMN Canada
- Employees
- GRFX N/A
- PMN N/A
- Industry
- GRFX
- PMN Pharmaceuticals and Biotechnology
- Sector
- GRFX
- PMN Health Care
- Exchange
- GRFX Nasdaq
- PMN Nasdaq
- Market Cap
- GRFX 18.1M
- PMN 18.8M
- IPO Year
- GRFX N/A
- PMN N/A
- Fundamental
- Price
- GRFX $0.75
- PMN $0.50
- Analyst Decision
- GRFX Hold
- PMN Strong Buy
- Analyst Count
- GRFX 1
- PMN 1
- Target Price
- GRFX N/A
- PMN $6.00
- AVG Volume (30 Days)
- GRFX 19.1K
- PMN 39.8K
- Earning Date
- GRFX 01-01-0001
- PMN 05-20-2025
- Dividend Yield
- GRFX 0.03%
- PMN N/A
- EPS Growth
- GRFX N/A
- PMN N/A
- EPS
- GRFX N/A
- PMN 0.11
- Revenue
- GRFX $24,184,100.00
- PMN N/A
- Revenue This Year
- GRFX N/A
- PMN N/A
- Revenue Next Year
- GRFX N/A
- PMN N/A
- P/E Ratio
- GRFX N/A
- PMN $4.69
- Revenue Growth
- GRFX N/A
- PMN N/A
- 52 Week Low
- GRFX $0.71
- PMN $0.51
- 52 Week High
- GRFX $2.75
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- GRFX 33.58
- PMN 35.83
- Support Level
- GRFX $0.93
- PMN $0.47
- Resistance Level
- GRFX $1.12
- PMN $0.60
- Average True Range (ATR)
- GRFX 0.11
- PMN 0.07
- MACD
- GRFX -0.01
- PMN -0.01
- Stochastic Oscillator
- GRFX 0.00
- PMN 12.80
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.